Resveratrol derivative, trans-3,5,4′-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation

Journal of Cellular Biochemistry

Volumn 109, Issue 2, 2010, Pages 339-346

  Alex, Deepa ^a   Leong, Emilia Conceição ^a   Zhang, Zai Jun ^a   Yan, Gloria Tse Ho ^b   Cheng, Shuk Han ^b   Leong, Chi Weng ^a   Li, Zhen Hua ^a   Lam, Kai Heng ^a   Chan, Shun Wan ^c   Lee, Simon Ming Yuen ^a  

^a University of Macau   (Macao)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

3,5,4 trimethoxystilbene; Angiogenesis; Cell cycle; Huvec; VEGFR2; Zebrafish

Indexed keywords

3,5,4' TRIMETHOXYSTILBENE; BASIC FIBROBLAST GROWTH FACTOR; MESSENGER RNA; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EMBRYO, NONMAMMALIAN; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; STILBENES; TRANSCRIPTION, GENETIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

DANIO RERIO;

EID: 74949086948     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22405     Document Type: Article

References (33)

1. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. 2007. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274-283.
2. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Tresta M. 2005. Antiangiogenic and vascular targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′- trimethoxystilbene. Mol Pharmacol 67:1451-1459.
3. Cai SX. 2007. Small molecule vascular disrupting agents: Potential new drugs for cancer treatment. Recent Patents Anticancer Drug Discov 2:79-101.
4. Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C. 2007. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z Naturforsch [C] 62:189-195.
5. Citrin D, Camphausen K. 2008. Advancement of antiangiogenic and vascular disrupting agents combined with radiation. Cancer Treat Res 139:153-171.
6. Crawford AD, Esguerra CV, de Witte PAM. 2008. Fishing for drugs from nature: Zebrafish as a technology platform for natural product discovery. Planta Medica 74:624-632.
7. Durrant D, Richards JE, Walker WT, Baker KA, Simoni D, Lee RM. 2008. Mechanism of cell death induced by cis-3,4′,5-trimethoxy-3′- aminostilbene in ovarian cancer. Gynecol Oncol 110:110-117.
8. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676.
9. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
10. Gescher AJ. 2008. Resveratrol from red grapes - Pedestrian polyphenol or useful anticancer agent? Planta Medica 74:1651-1655.
11. Kanthou C, Tozer GM. 2007. Tumor targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 11:1443-1457.
12. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O, Tozer G. 2004. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165:1401-1411.
13. Lam HW, Lin HC, Lao SC, Gao JL, Hong SJ, Leong CW, Yue PY, Kwan YW, Leung AY, Wang YT, Lee SM. 2008. The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem 103:195-211.
14. Langheinrich U. 2003. Zebrafish: A new model on the pharmaceutical catwalk. Bioessays 25:904-912.
15. Lawson ND, Wienstein BM. 2002. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248:307-318.
16. Lee EJ, Min HY, Joo Park H, Chung HJ, Kim S, Nam Han Y, Lee SK. 2004. G2/M cell cycle arrest and induction of apoptosis by a stilbenoid, 3,4,5-trimethoxy-4′-bromo-cis-stilbene, in human lung cancer cells. Life Sci 75: 2829-2839.
17. Leong CW, Wong CH, Lao SC, Leong EC, Lao IF, Law PT, Fung KP, Tsang KS, Waye MM, Tsui SK, Wang YT, Lee SM. 2007. Effect of resveratrol on proliferation and differentiation of embryonic cardiomyoblasts. Biochem Biophys Res Commun 360:173-180.
18. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J. 2007. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134:839-844.
19. Lu R, Serrero G. 1999. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179:297-304.
20. Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA, Lavasanifar A. 2008. Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol 63:27-35.
21. Norrby K. 2006. In vivo models of angiogenesis. J Cell Mol Med 10:588-612.
22. Notas G, Nifli AP, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. 2006. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta 1760:1657-1666.
23. O'Reilly MS. 2007. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 69:S64-S66.
24. Pan MH, Gao JH, Lai CS, Wang YJ, Chen WM, Lo CY, Wang M, Dushenkov S, Ho CT. 2008. Antitumor activity of 3,5,4′-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog 47:184-196.
25. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P, Zappia V. 1998. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250:53-58.
26. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gossé F, Launay JF, Brouillard R, Raul F. 2003. Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107:189-196.
27. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM. 1999. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412-5416.
28. Siemann DW, Chaplin DJ, Horsman MR. 2004. Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499.
29. Simoni D, Roberti M, Invidiata FP, Aiello E, Aiello S, Marchetti P, Baruchello R, Eleopra M, Di Cristina A, Grimaudo S, Gebbia N, Crosta L, Dieli F, Tolomeo M. 2006. Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett 16:3245-3248.
30. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V. 2001. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276:22586-22594.
31. Thisse C, Thisse B, Schilling TF, Postlethwait JH. 1993. Structure of the zebrafish snail1 gene and its expression in wild-type, spadetail and no tail mutant embryos. Development 119:1203-1215.
32. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. 2007. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov 2:59-71.
33. Westerfield M. 1993. The zebrafish book: A guide for the laboratory use of zebrafish. Eugene, OR: The University of Oregon Press.